MPMariana Prokopovych

Mariana Prokopovych

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Prokopovych has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Virological and Antifibrotic Efficacy of Antiviral Treatment for Hepatitis В+C in HIV-positive Patients

    by Mariana Prokopovych, Ihor Hryzhak

    Aim: To study and compare the efficacy of different regimens of combination antiviral therapy for hepatitis C and B in achieving a sustained virological response in patients with HIV/HBV/HCV coinfection and their impact on the degree of liver fibrosis. Material and methods: We examined 113 HIV-infected adult patients with HBV/HCV coinfection who were registered at the Municipal Non-profit Enterprise “Infectious Diseases Center of the Ivano-Frankivsk Regional Council” between 2017 and 2019. Results: The treatment regimens with two direct-acting antivirals (sofosbuvir/ledipasvir, sofosbuvir+daclatasvir, sofosbuvir/velpatasvir and sofosbuvir/ledipasvir and ribavirin resulted in 100 % sustained virologic response. The efficacy of the pegylated interferon, sofosbuvir, and ribavirin regimen was lower, with sustained virologic response achieved in 86.2 % of patients. The lowest efficacy was observed with the sofosbuvir and ribavirin regimen – sustained virologic response achieved in 75.0 % of patients. Primary HBV resistance to tenofovir/emtricitabine was identified in 1.76 % of patients in the entire cohort. Among patients in the group treated with combined antiviral therapy for HBV and HCV using tenofovir/emtricitabine and direct-acting antivirals with or without ribavirin, the incidence of liver fibrosis F3-F4, as assessed by point-shear wave elastography, decreased from 20 % to 2.5 % (р<0,05) after one year of follow-up. Conclusions: In patients with HIV/HBV/HCV coinfection, interferon-free regimens that include two direct-acting antivirals, either alone or in combination with ribavirin, demonstrated 100 % virologic efficacy and the most beneficial effects on the liver reducing the degree of liver fibrosis.

  • Open Access

    Subacute Sclerosing Encephalitis in an Adult with Congenital HIV Infection – Case Report

    by Ihor Hryzhak, Olexandra Pryshlyak, Victoria Gryb, Marianna Prokopovich, Mykola Prokofiev, Olga Matviiuk, Nataliya Diomina, Lilia Hryzhak

    Subacute sclerosing panencephalitis (SSPE) is the result of a chronic infection of the central nervous system caused by a mutated measles virus. We present a case of SSPE in a 19-year-old female with congenital HIV-infection. The patient has been using antiretroviral therapy regularly since she was 4 years old. At the age of 15, she contracted measles of moderate severity. At the age 17, she had the HIV viral load < 20 copies/ml and the CD4 count 420 cells/μl. Three years after measles, bilateral necrotizing retinitis developed, and five months later, myoclonic seizures of the left limbs. Symptoms progressed gradually, with fever, generalised seizures, and lost consciousness. She was hospitalized in department for treatment patient with HIV-infection. Magnetic resonance imaging of the brain revealed massive areas of the altered signal without clear contours in both hemispheres of the brain, which captured the white and grey matter of the fronto-parietal, temporal-occipital lobes. The electroencephalography showed the flashes of slow-wave paroxysmal activity of the brain in the delta range, mainly in the fronto-parietal area. In the cerebral spinal fluid, anti-measles IgG was detected at a titre of 3738,408 U/ml, and in the blood – 9.4 U/ml. A diagnosis of SSPE was established. Supportive, corticosteroids and anticonvulsant treatment were ineffective. Patient died 10 months after the onset of the disease. Therefore, measles at any age in a person with congenital HIV-infection poses a risk of developing SSPE.


  • Open Access

    PATHOMORPHOLOGICAL CHANGES IN THE LIVER CAUSED BY HEPATITIS B, C, B+C VIRUSES IN THE DECEASED HIV-INFECTED PERSONS

    by M. V. Prokopovych, I. H. Hryzhak, M. M. Bahrii, V. M. Kostyuk, І. Г. Грижак

    Pathohistological peculiarities of liver histological preparations of 75 HIV-infected deceased people with chronic viral hepatitis which diagnosed during their life: hepatitis B was in 8, C – in 24, B+C – in 43 patients. It was determined that in all patients (100.0 %), with any type of chronic hepatitis (B, C or B+C) there was a lymphocyte-macrophage infiltration of portal tracts and stroma. In persons with hepatitis B there were a focal and periportal necrosis of hepatocytes in 100.0 % of patients, hydropic dystrophy of hepatocytes - in 87.5 % and liver cirrhosis – in 25.0 %. In patients with hepatitis C a fatty dystrophy of the liver was found in 91.7 % that more often than in patients with hepatitis B (12.5 %, p<0.001), the focal periportal necrosis of hepatocytes was less (12.5 % vs. 100.0 %, respectively, p<0.001) and liver cirrhosis was in 41.7 %. In patients with hepatitis B+C, the liver tissue included signs characteristic of both hepatitis B and C: a hydropic dystrophy (69.8 %), fatty dystrophy (30.2 %), periportal bridging necrosis (51.2 %), liver fibrosis (34.9 %). As a result of these complex pathological processes in the liver, a cirrhosis was found more often than in other groups of patients (67.4 % vs. 41.7 % of patients with hepatitis C, p=0.041, and vs. 25.0 % of patients with hepatitis B, p=0.024). Histology activity index of hepatitis and stage of liver fibrosis according to Knodell R.G. (1981) did not differ in frequency in all groups of patients. In all patients a strong negative correlation was found between them (r=-0.607, p<0.001). This finding reflects a decrease in the histological activity of hepatitis against the background of increased fibrotic changes in the body. Conclusion. It has been found that the hydropic dystrophy and focal intralobular and periportal bridging necrosis of hepatocytes are characteristic of hepatitis B infection in HIV-infected deceased persons. Hepatitis C is characterized by the fatty dystrophy and cirrhosis of the liver. The presence of hepatitis B+C causes the liver changes characteristic of both hepatitis B and C simultaneously: the hydropic dystrophy, fatty dystrophy, necrosis of hepatocytes. The liver cirrhosis is most often present in patients with hepatitis B+C. The degree of liver fibrosis negatively correlated with the histology activity index of hepatitis.

  • Open Access

    Досвід застосування тоцилізумабу у хворих на COVID-19 в Івано-Франківській області

    by I.H. Hryzhak, O.YA. Pryshlyak, O.V. Marynchak, R.M. Mizyuk, O.V. Kopchak, V.I. Kvasnyuk, M.V. Prokopovich, A.V. Kucher, L.Y. Samotovka

    Вступ. Для усунення ефектів «цитокінового шторму» у хворих на COVID-19 призначають глюкокортикостероїди, а в тяжких випадках — тоцилізумаб. Мета. Вивчити ефективність тоцилізумабу у хворих на коронавірусну хворобу COVID-19 із тяжким перебігом та дихальною недостатністю в умовах відділення інтенсивної терапії. Матеріал і методи. Ретроспективний аналіз 20 випадків захворювання на COVID-19 із критичним перебігом. Середній вік пацієнтів — 59,8±1,9 року. Пацієнти перебували у відділенні інтенсивної терапії, І група — 10 осіб отримували тоцилізумаб із курсовою дозою 800 мг; ІІ група — 10 осіб тоцилізумаб не отримували. Пацієнти обох груп не отримували противірусні засоби та внутрішньовенний людський нормальний імуноглобулін. Визначали коагулограму, СРБ, D-димери, ІЛ-6, прокальцитонін. Статистична обробка результатів проводилася непараметричними методами з використанням U-критерію Манна — Вітні і критерію знаків G. Результати. У групі І спостерігався лейкоцитоз у межах 8,9-15,5×109/л, лімфопенія — у межах 0,69-2,1×109/л, еозинопенія — 0-1%, нейтрофільно-лімфоцитарний індекс — 3,1-14,9; ШОЕ — 24-53 мм/год, СРБ — 58-125 мг/л, ІЛ-6 — 109-2196 пг/мл, прокальцитонін — 0,6-4,7 нг/мл. У ІІ групі дані показники мали аналогічне значення. У результаті застосування тоцилізумабу не спостерігалось значного клінічного покращення загального стану пацієнтів. У І групі 7 (70,0%) пацієнтів померли, а летальність у ІІ групі становила 5 (50%) осіб, p>0,05. Виявлено факт появи гіперлейкоцитозу (26,4-39,4×109/л) у частини пролікованих тоцилізумабом хворих — 6 (60,0%), який виникав через 1-2 дні після введення препарату й утримувався впродовж 13-20 днів, якщо пацієнти виживали. Висновки. Призначення тоцилізумабу в курсовій дозі 800 мг не дало статистично достовірного ефекту підвищення виживаності хворих на COVID-19 із критично тяжким перебігом у зв’язку з відсутністю попереднього призначення противірусних засобів та раціональної корекції антибіотикотерапії.